4.6 Article

P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

Journal

CLINICAL NEUROPHYSIOLOGY
Volume 130, Issue 8, Pages e170-e171

Publisher

Elsevier BV
DOI: 10.1016/j.clinph.2019.04.704

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available